지원사업
학술연구/단체지원/교육 등 연구자 활동을 지속하도록 DBpia가 지원하고 있어요.
커뮤니티
연구자들이 자신의 연구와 전문성을 널리 알리고, 새로운 협력의 기회를 만들 수 있는 네트워킹 공간이에요.
초록· 키워드
오류제보하기
Background: Hypertension is one of the major risk factors for stroke, heart attack, heart failure and kidney failure, thereby causing deaths and disability world-wide. The most predominant type of HTN is essential hypertension (HTN). Unani scholars have mentioned about the clinical manifestations and management of the hypertension and documented it in the context of ‘Imtila’. The drug Sankhaholi (Evolvulus alsinoides Linn.) is one of the widely prescribed medicines for the management of essential hypertension in Unani medicine.
Material and Methods: The present clinical study was carried out to evaluate the safety of Sankhaholi (Evolvulus alsinoides Linn.) in the management of stage-1 essential hypertension. Newly diagnosed 41 patients of Essential Hypertension (22 patients were in the test group and 19 patients in the control group) were enrolled for the study. All the patients in the test group were given with the test drug 3 g powder of Sankhaholi twice a day for 6 weeks orally. Patients in the control group were given standard drug Ramipril 5 mg once a day for the same duration. Clinical as well as hematological parameters were recorded before and after the treatment.
Results: No significant changes are recorded in safety parameters viz. CBC, Haemogram, LFT and KFT. Clinically no adverse effect of the drug has been reported during the course of treatment. Also, significant effect on the systolic blood pressure (p<0.001) were recorded in test group. The drug Sankhaholi was also found effective on the symptoms associated with hypertension.
Conclusion: The finding of the study revealed that the test drug Sankhaholi (Evolvulus alsinoides Linn.) is safe and has substantial efficacy as an antihypertensive drug.
Material and Methods: The present clinical study was carried out to evaluate the safety of Sankhaholi (Evolvulus alsinoides Linn.) in the management of stage-1 essential hypertension. Newly diagnosed 41 patients of Essential Hypertension (22 patients were in the test group and 19 patients in the control group) were enrolled for the study. All the patients in the test group were given with the test drug 3 g powder of Sankhaholi twice a day for 6 weeks orally. Patients in the control group were given standard drug Ramipril 5 mg once a day for the same duration. Clinical as well as hematological parameters were recorded before and after the treatment.
Results: No significant changes are recorded in safety parameters viz. CBC, Haemogram, LFT and KFT. Clinically no adverse effect of the drug has been reported during the course of treatment. Also, significant effect on the systolic blood pressure (p<0.001) were recorded in test group. The drug Sankhaholi was also found effective on the symptoms associated with hypertension.
Conclusion: The finding of the study revealed that the test drug Sankhaholi (Evolvulus alsinoides Linn.) is safe and has substantial efficacy as an antihypertensive drug.
목차
ABSTRACT
INTRODUCTION
MATERIAL AND METHODS
RESULTS
DISCUSSION
CONCLUSION
REFERENCES
참고문헌 (0)
참고문헌 신청함께 읽어보면 좋을 논문
논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!
-
Evolvulus alsinoides: A potential antihypertensive herb
셀메드
2019 .11
-
Risks and management of hypertension in cancer patients undergoing targeted therapy: a review
Clinical Hypertension
2022 .01
-
2018 Korean Society of Hypertension guidelines for the management of hypertension: part I-epidemiology of hypertension
Clinical Hypertension
2019 .01
-
A 2020 Vision of Hypertension
Korean Circulation Journal
2020 .01
-
Highlights of the 2018 Chinese hypertension guidelines
Clinical Hypertension
2020 .01
-
Application of artificial intelligence in hypertension
Clinical Hypertension
2024 .01
-
Erratum : Effect of Hypertension on Childhood-onset Systemic Lupus Erythematous in a Tertiary Medical Center in Korea
Childhood Kidney Diseases
2021 .01
-
Korea hypertension fact sheet 2020: analysis of nationwide population-based data
Clinical Hypertension
2021 .01
-
Clinical characteristics and prognosis of patients with very severe acute hypertension visiting the emergency department
Clinical Hypertension
2022 .01
-
2013 Korean Society of Hypertension guidelines for the management of hypertension. Part II—treatments of hypertension
Clinical Hypertension
2015 .01
-
Updated Reasons and Clinical Implications of New Korean Hypertension Guidelines for Cardiologists
Korean Circulation Journal
2020 .01
-
Sex-Specific Trends in the Prevalence of Hypertension and the Number of People With Hypertension: Analysis of the Korea National Health and Nutrition Examination Survey (KNHANES) 1998?2018
Korean Circulation Journal
2022 .05
-
비노인군과 노인군 고혈압 환자의 고혈압 관리
한국보건간호학회지
2017 .08
-
2013 Korean Society of Hypertension guidelines for the management of hypertension. Part III—hypertension in special situations
Clinical Hypertension
2015 .01
-
Gender Differences in Hypertension Control Among Older Korean Adults: Korean Social Life, Health, and Aging Project
예방의학회지
2015 .01
-
An economic evaluation of intensive hypertension control in CKD patients: a cost-effectiveness study
Clinical Hypertension
2022 .01
-
The Relationship between Family History and Hypertension by Serum Glucose Levels and Age in Korean Men and Women
대한의생명과학회지
2022 .12
-
일개 한의원의 고혈압 한의치료 118례에 대한 고찰
대한한방내과학회지
2018 .01
-
Korea hypertension fact sheet 2022: analysis of nationwide population-based data with a special focus on hypertension in the elderly
Clinical Hypertension
2023 .01
-
2018 Korean society of hypertension guidelines for the management of hypertension: part III-hypertension in special situations
Clinical Hypertension
2019 .01
이 논문의 저자 정보
이 논문과 함께 이용한 논문
최근 본 자료
댓글(0)
0
UCI(KEPA) : I410-ECN-0101-2023-470-001310241